Intec Pharma — Investor Presentation (March 2017)
35 slides from Intec Pharma's investor presentation, Mar 23, 2017
Slide 1: Corporate Presentation: Unfolding drug delivery solutions
Corporate Presentation Nasdaq/TASE: NTEC March 2017 Unfolding drug delivery solutions
Slide 2: Forward Looking Statements
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 2 Forward Looking Statements This presentation by Intec Pharma Ltd. (referred to as “we” or “our”) contains forward - looking statements about our expectations , beliefs and intentions regarding, a
Slide 3: Table of Contents
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 3 Table of Contents 1. Executive Summary 2. AP - CD/LD for Parkinson’s Disease: Our Approach for an Unmet Medical Need 3. AP - CD/LD for Parkinson’s Disease: Clinical Development 4. AP - CBD/THC Ca
Slide 4: 1. Executive Summary
INTEC PHARMA 1. Executive Summary
Slide 5: Experienced Management Team
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 5 Zeev Weiss, BSc, CPA Chief Executive Officer Former Head of Life Sciences Strategic Consulting, PwC Israel More than 15 years of experience in healthcare corporate development and strategic p
Slide 6: Executive Summary
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 6 Executive Summary A Late - stage drug development company utilizing a proprietary oral drug delivery system – the Accordion Pill TM (AP) • The Accordion Pill, currently in clinical testing, is
Slide 7: Accordion Pill Platform Technology
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 7 Executive Summary Combines drugs and inactive ingredients into multiple polymeric films that are layered into a planar structure, folded into t he shape of an accordion and placed inside a stan
Slide 8: Our Unique Accordion Pill Drug Delivery Process
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 8 Executive Summary Our Unique Accordion Pill Drug Delivery Process AP movie.wmv
Slide 9: Drugs Particularly Suited to the Accordion Pill Platform
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 9 Executive Summary Narrow Absorption Window: drug absorption is confined mainly to the upper part of the GI tract, with poor colonic absorption Low solubility. For poorly soluble drugs , the A
Slide 10: Product Pipeline
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 10 Executive Summary Product Pipeline ( 1 ) Developed under 505 (b)( 2 ). Intec Pipeline Product Candidate Research Phase I Phase II Phase III Next Steps AP - CD/LD (1) Parkinson's disease symptoms
Slide 11: Recent/Upcoming Milestones
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 11 Executive Summary Recent/Upcoming Milestones Q 1 : 2016 Q2:2016 Q 3 : 2016 Q 4 : 2016 Q 1 : 2017 Q 3 : 2017 Q 2 : 2017 Q 4 : 2017 Q 2 : 2016 : Enrolled first patient in pivotal Phase III clinica
Slide 12: Capital Structure, Cash and Institutional Holders
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 12 Executive Summary $ $ 21.4 M in cash and short term bank deposits and financial assets as of June 30 , 2016 $5.2M Approved grant from the Israeli National Authority for Technological Innovation
Slide 13: 2. AP-CD/LD for Parkinson's Disease: Unmet Medical Need
2 . AP - CD/LD for Parkinson’s Disease : Our Approach for an Unmet Medical Need
Slide 14: Parkinson's Disease Market Overview
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 14 AP - CD/LD for Parkinson’s Disease: Our Approach for an Unmet Medical Need The second most common neurodegenerative disorder in elderly, affecting 1% – 2% of individuals ages ≥65 years worldwi
Slide 15: Limited Success of Current Levodopa Delivery Efforts
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 15 AP - CD/LD for Parkinson’s Disease: Our Approach for an Unmet Medical Need Current efforts to provide stable, therapeutic levodopa levels, with easy - to - use delivery, have had limited success
Slide 16: AP-CD/LD New Paradigm Product Concept
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 16 AP - CD/LD for Parkinson’s Disease: Our Approach for an Unmet Medical Need AP - CD/LD introduces a new approach: AP - CD/LD New Paradigm Product Concept: BID or TID administration of AP - CD/LD
Slide 17: 3. AP-CD/LD for Parkinson's Disease: Clinical Development
3 . AP - CD/LD for Parkinson’s Disease: Clinical Development
Slide 18: Clinical Steering and Enrollment Committees
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 18 Warren Olanow , MD Karl Kieburtz, MD, MPH AP - CD/LD for Parkinson’s Disease: Clinical Development AP - CD/LD Clinical Steering and Enrollment Committees Peter A. LeWitt , MD Robert Hauser, MD,
Slide 19: AP-CD/LD Phase II Trial Structure
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 19 AP - CD/LD for Parkinson’s Disease: Clinical Development AP - CD/LD Phase II Trial Structure (a) Eight patients completed the PK trial. (b) Group 5 was terminated early due to low enrollment. d
Slide 20: Phase II Advanced Patients, Multi-dose PK
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 20 AP - CD/LD for Parkinson’s Disease: Clinical Development Phase II, Advanced Patients , Multi - dose PK (Group 3 ) Trial Design Screening Randomization 6 days Day 7 6 days Day 7 PK PK AP - CDLD 5
Slide 21: Phase II Advanced Patients, 21 Days Treatment Trial Design
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 21 AP - CD/LD for Parkinson’s Disease: Clinical Development Significantly Reduced TSD Significantly Reduced OFF Time Screening Randomization 17 days conversion 4 days 17 days optimization 4 days te
Slide 22: AP-CD/LD Phase III Accordance Trial Design
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 22 AP - CD/LD for Parkinson’s Disease: Clinical Development Design: • Multi - center, global, randomized, double - blind, double - dummy, active - controlled, parallel - group study in adult pati
Slide 23: AP-CD/LD Phase III Trial Design
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 23 AP - CD/LD for Parkinson’s Disease: Clinical Development AP - CD/LD Phase III Trial Design 4 Weeks 6 Weeks 13 Weeks 2 Weeks With reference drug = Sinemet 50 / 400 , 50 / 500 BID, TID Open label
Slide 24: AP-CD/LD Development Timeline
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 24 AP - CD/LD for Parkinson’s Disease: Clinical Development AP - CD/LD Development Timeline AP - CD/LD Trial Status 2016 2017 2018 2019 Q2:2016: First patient enrolled in Phase III trial Q4:201
Slide 25: 4. AP-CBD/THC Cannabinoid Therapy
4 . AP - CBD/THC Cannabinoid Therapy
Slide 26: AP-CBD/THC Cannabinoid Therapy
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 26 Market Opportunity Intec’s Solution Under Development AP - CBD/THC Cannabinoid Therapy AP - CBD/THC Cannabinoid Therapy ( 1 ) Source: Viridian Capital Advisors. ( 2015 , December 2 ). REPORT: Th
Slide 27: 5. AP-Zaleplon (ZP) for Insomnia
5 . AP - Zaleplon (ZP) for Insomnia
Slide 28: AP-ZP for Insomnia
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 28 AP - ZP for Insomnia In 2013 , there were approximately 140 MM prevalent cases of chronic insomnia in the Seven Major Markets ( 1 )( 2 )( 3 ) The sleep disorder drug market in these markets
Slide 29: AP-ZP for Insomnia
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 29 AP - ZP for Insomnia AP - ZP contains Zaleplon (generic Sonata) in both immediate and controlled release forms Zaleplon is approved for sleep induction. Its short half life (~ 1 hour) result
Slide 30: 6. AP Platform for Poorly Soluble Drugs
7 . AP Platform for Poorly Soluble Drugs
Slide 31: AP Platform for Poorly Soluble Drugs
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 31 AP Platform for Poorly Soluble Drugs The AP platform technology is also designed for drugs with low solubility, namely Biopharmaceutics Classification System, or BCS , Class II (low solubility
Slide 32: Accordion Pill with Poorly Soluble Drugs: PK Clinical Study
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 32 AP Platform for Poorly Soluble Drugs PK issues of drug X include only 30 % absorption and lack of dose proportionality above an approved marketed dose ( Xmg ) AP significantly extended the a
Slide 33: 7. IP Overview
INTEC PHARMA 7. IP Overvie
Slide 34: Three Layers of IP Protection
13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 34 IP Overview Platform IP • Various Accordion Pill dosage forms • Latest US patent expires in 2029 Manufacturing IP • Methods for making/folding gastroretentive drug delivery system • US paten
Slide 35: Thank You
THANK YOU INTEC PHARMA LTD. 12 Hartom st. (RMPE building) P.O. Box 45219 Jerusalem 9777512 Israel Tel: + 972 - 2 - 5864657 Fax: + 972 - 2 - 5869176 [email protected]